teva | Oncology | Canada

Brands. Generics.
**Biosimilars.**

## A Herceptin® (trastuzumab) biosimilar available in Canada[1]



Creative representation of a molecule.

# PrHerzuma®
*Trastuzumab for Injection*
*440 mg/vial Intravenous Infusion*

## Biosimilar by design. Biologic by essence.

### Early Breast Cancer (EBC)[1]*

HERZUMA® (trastuzumab) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2,

- following surgery and after chemotherapy
- following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel
- in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.

### Metastatic Breast Cancer (MBC)[1]*

HERZUMA® is indicated for the treatment of patients with MBC whose tumours overexpress HER2.

### Metastatic Gastric Cancer (MGC)[1]*

HERZUMA® in combination with capecitabine or intravenous 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

## HERZUMA®: A proud offering from Teva Canada Innovation.

**For more information:**
Please consult the Product Monograph at https://pdf.hres.ca/dpd_pm/00052973.PDF for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, administration and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling Teva Canada Innovation at 1-833-662-5644.

PrHerzuma®
*Trastuzumab for Injection*
*440 mg/vial Intravenous Infusion*

* Indications have been granted on the basis of similarity between HERZUMA® and the reference biologic drug Herceptin®.

**Reference: 1.** PrHERZUMA® Product Monograph. Teva Canada Limited. September 3, 2019.



09/2021
HER19-ADG01E